A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

Sasanlimab combined with BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's results suggest potential paradigm shifts in ...

The test can provide results in 48 minutes to provide diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.

“As long as APPs are properly supported, they will take off and they will change your practice,” says Mark T. Edney, MD. In this video, Mark T. Edney, MD, discusses how to foster a collaborative ...

TYRA-300's phase 2 trial in NMIBC aims to evaluate safety and efficacy, enrolling up to 90 patients with FGFR3 alterations. The primary endpoint is the complete response rate at 3 months, with ...

At a median follow-up of 33.2 months, the confirmed objective response rate was 73.2%. The NMPA’s approval was supported by data from the phase 3 EV-302 trial.

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies ...

A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), ...

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias ...

"Studying the microbiome overall is challenging because it's dirty science. You have to be incredibly careful with contamination," says Ilaha Isali, MD, MSc, and Laura Bukavina, MD, MPH, MSc. Isali: ...

9MW2821 combined with toripalimab received breakthrough therapy designation for advanced urothelial carcinoma, enhancing development and review processes. Initial study results showed an 87.5% ...